Skip to main content
Log in

Excretion of tacrolimus glucuronides in human bile

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Tacrolimus is extensively metabolized by the cytochrome P-450 system. Hepatic metabolic phase I reactions of tacrolimus include mainly demethylation and/or hydroxylation. No valid data have been published on phase II pathways (glucuronide- or sulfo-conjugation). In order to investigate these pathways, different β-glucuronidase/sulfatase enzyme preparations were used to hydrolyse the conjugates potentially present in human bile extracts. Two analytical methods were used: a non-specific method, MEIA, and a specific combined HPLC/MEIA method. The influence of the extraction pH was investigated. After β-glucuronidase hydrolysis and extraction at pH 5, tacrolimus concentrations, obtained either from HPLC-MEIA or MEIA, always appeared significantly higher, suggesting the presence of glucuronides in the bile. When the extraction was performed at pH 1.5, only the HPLC-MEIA concentrations appeared higher after hydrolysis. MEIA concentrations obtained before and after hydrolysis were similar. These data are consistent with the fact that glucuronides are extracted at pH 1.5 but not at pH 5 and suggest first that, without hydrolysis, the extracted glucuronides are separated from the tacrolimus fraction in the HPLC-MEIA procedure, and second, that the glucuronides are cross-detected by the monoclonal antibody in the immunoassay. From these data, it is concluded that clues have been found, suggesting the presence in human bile of tacrolimus glucuronides, which cross-react with the monoclonal antibody, provided they are extracted in the sample tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Venkataramanan R., Jain A., Cadoff E. et al. (1990): Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant. Proc., 22 (suppl 1) 52–56.

    CAS  PubMed  Google Scholar 

  2. Christians U., Kruse C., Kownatzki R. et al. (1991): Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant. Proc., 23 940–941.

    CAS  PubMed  Google Scholar 

  3. Shah I.A., Whiting P.H., Omar G., Thomson A.W., Burke M.D. (1991): Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant. Proc., 23, 2783–2785.

    CAS  Google Scholar 

  4. Sattler M., Guengerich F.P., Yun C.H., Christians U., Sewing F.K. (1992): Cytochrome P-450 3A enzymes are responsible for biotransformation of FK 506 and rapamycin in man and rat. Drug Metab. Dispos., 20, 753–761.

    CAS  PubMed  Google Scholar 

  5. Stiff D.D., Venkataramanan R., Tara T.N.V. (1992): Metabolism of FK 506 in differentially induced rat liver microsomes. Res. Commun. Chem. Pathol., 78, 121–124.

    CAS  Google Scholar 

  6. Vincent S.H., Karanam B.V., Painter S.K., Chiu S.H.L. (1992): In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch. Biochem. Biophys., 294, 454–460.

    Article  CAS  PubMed  Google Scholar 

  7. Christians U., Braun F., Kosian N. et al. (1991): High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile and urine of liver grafted patients. Transplant. Proc., 23, 2741–2744.

    CAS  PubMed  Google Scholar 

  8. Iwasaki K., Shiraga T., Matsuda H., Nagase K. (1995): Identification and biological activities of the metabolites oxidised at multiple sites of FK506. Drug Metab. Dispos., 23, 28–34.

    CAS  PubMed  Google Scholar 

  9. Lhoëst G., Maton N., Verbeeck R. (1993): Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. Drug Metab. Dispos., 21, 850–854.

    PubMed  Google Scholar 

  10. Venkataramanan R., Swaminathan A., Prasad T. et al. (1995): Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet., 29, 404–430.

    Article  CAS  PubMed  Google Scholar 

  11. Miners J.O. Lillywhite K.J., Yoovathaworn K., Pongmarutal M., Birkett D.J. (1990): Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. Biochem. Pharmacol., 40, 595–600.

    Article  CAS  PubMed  Google Scholar 

  12. George A., Hazelton, Curtis D., Klaassen (1988): UDP-Glucuronosyltransferase activity toward digitoxigenin-monodigitoxoside. Drug Metab. Dispos., 16, 30–36.

    Google Scholar 

  13. Firdaous I., Hassoun A., Otte J.B. et al. (1995): HPLC-Microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. Clin. Chem., 41, 1292–1296.

    CAS  PubMed  Google Scholar 

  14. Kroemer H.K., Klotz U. (1992): Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet., 23 292–310.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Firdaous, I., Vėrbeeck, R.K., Hassoun, A. et al. Excretion of tacrolimus glucuronides in human bile. European Journal of Drug Metabolism and Pharmacokinetics 22, 217–221 (1997). https://doi.org/10.1007/BF03189810

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189810

Keywords

Navigation